2-hydroxypyridine has been researched along with Parkinson Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Díaz-de-Villegas, MD; Gálvez, JA; José Galano-Frutos, J; Mahía, A; Navarro, S; Pallarés, I; Peña-Díaz, S; Pujols, J; Sancho, J; Ventura, S | 1 |
| Almqvist, F; Foderà, V; Horvath, I; Nors Perdersen, M; Nørgaard Toft, K; van Maarschalkerweerd, A; Vestergaard, B; Weise, C; Wittung-Stafshede, P; Wolf-Watz, M | 1 |
| Almqvist, F; Andersson, EK; Bengtsson, C; Chapman, M; Chorell, E; Horvath, I; Hultgren, SJ; Olofsson, A; Sellstedt, M; Weise, CF; Wittung-Stafshede, P; Wolf-Watz, M | 1 |
| Almqvist, F; Horvath, I; Krishna Prasad, G; Larsson, G; Nordvall, LM; Olofsson, A; Sellstedt, M; Weise, C; Wittung-Stafshede, P | 1 |
4 other study(ies) available for 2-hydroxypyridine and Parkinson Disease
| Article | Year |
|---|---|
Design, synthesis and structure-activity evaluation of novel 2-pyridone-based inhibitors of α-synuclein aggregation with potentially improved BBB permeability.
Topics: alpha-Synuclein; Animals; Blood-Brain Barrier; Caenorhabditis elegans; Dose-Response Relationship, Drug; Drug Design; Molecular Structure; Parkinson Disease; Protein Aggregates; Pyridones; Structure-Activity Relationship | 2021 |
Direct Correlation Between Ligand-Induced α-Synuclein Oligomers and Amyloid-like Fibril Growth.
Topics: alpha-Synuclein; Alzheimer Disease; Amyloid; Amyloidogenic Proteins; Humans; Ligands; Parkinson Disease; Protein Aggregation, Pathological; Protein Structure, Secondary; Pyridones | 2015 |
Mechanisms of protein oligomerization: inhibitor of functional amyloids templates α-synuclein fibrillation.
Topics: alpha-Synuclein; Amyloid; Anti-Bacterial Agents; Escherichia coli; Escherichia coli Proteins; Humans; Parkinson Disease; Pyridones | 2012 |
Modulation of α-synuclein fibrillization by ring-fused 2-pyridones: templation and inhibition involve oligomers with different structure.
Topics: alpha-Synuclein; Amyloid; Antiparkinson Agents; Humans; Parkinson Disease; Protein Structure, Secondary; Pyridones | 2013 |